BAY 3713372

BAY 3713372 is an investigational, oral small molecule that acts as a potent and selective MTA-cooperative inhibitor of protein arginine N-methyltransferase 5 (PRMT5). It is being developed for the treatment of solid tumors with deletions in the methylthioadenosine phosphorylase (MTAP) gene. The drug exploits a synthetic lethality approach by selectively inhibiting PRMT5 in MTAP-deleted cancer cells, which are particularly vulnerable due to their altered methionine metabolism. This targeted mechanism aims to kill tumor cells while sparing normal tissue. Notably, BAY 3713372 demonstrates brain penetrance, enabling it to target both central nervous system metastases and primary brain tumors. The compound originated from Puhe BioPharma (as PH020) and is now being developed globally by Bayer following a licensing agreement[1][3][5][6][7][8].

Other names

MTA-cooperative PRMT5 inhibitor